A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Clinical trial NCT03343054 · COMPLETED

Trial details

NCT number: NCT03343054
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Neoplasms Breast Neoplasms

Start date: 2017-11-30
Primary completion: 2021-01-11
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.